MYC and metastatic neoplasm: The ongoing pan-European SIOP PNET 5 MB clinical trial defines standard-risk, non-infant disease as the absence of high-risk clinical features such as metastatic disease or subtotal resection, molecular features (MYC or MYCN amplification or TP53 mutation in SHH medulloblastoma), and histological characteristics (large-cell/anaplastic disease).